바이오인

 

 

Monitoring, Control, and Treatment of Diabetes Is a Significant Unmet Need in Medicine
Steven Heffner

Diabetes is now one of the most common noncommunicable diseases globally. It is the fourth or fifth leading cause of death in most developed countries. There also is substantial evidence that it is epidemic in many developing and newly industrialized nations.

 

Diabetes is certain to be one of the most challenging health problems in the 21st century. Complications from diabetes such as coronary artery and peripheral vascular disease, stroke, diabetic neuropathy, amputations, renal failure, and blindness are resulting in increasing disability, reduced life expectancy, and enormous health cost for virtually every society.

 

It is no surprise then that the monitoring, control, and treatment of diabetes mellitus and its downstream complications has been and will continue to be a major of biomedical research and development efforts. The industry is ed on metabolic disease for good reason-it represents one of the greatest areas of unmet need in medicine, and the market opportunity is open and increasing.

 

In the top-seven markets, the potential for monitoring and treating the disease as well as treating the direct complications of the disease will exceed $70 billion in 10 years. This is a significant incentive to development.........이하생략